A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

The study aims to provide an adequate procedural framework to support and facilitate collection of existing participant samples from patients who were diagnosed with secondary malignancy of T-cell origin any time after tisagenlecleucel treatment for testing of muCAR19 transgene and RCL, as well as additional analyses as warranted. Formal testing of existing tumor tissue and/or blood DNA will assess a potential role of tisagenlecleucel in the development/oncogenesis of secondary malignancy of T-cell origin.

NCT Number	NCT07378969
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Secondary Malignancies of T-cell Origin
Enrollment	30 participants
Start Date	2026-03-23
Primary Completion	2039-08-31 (estimated)
Study Completion	2039-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-11